Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis

Abstract Objective To assess the effects of corticosteroids on mortality in patients with severe sepsis and septic shock. Data sources Randomised and quasi-randomised trials of corticosteroids versus placebo (or supportive treatment alone) retrieved from the Cochrane infectious diseases group's trials register, the Cochrane central register of controlled trials, Medline, Embase, and LILACS. Review method Two pairs of reviewers agreed on eligibility of trials. One reviewer entered data on to the computer and four reviewers checked them. We obtained some missing data from authors of trials and assessed methodological quality of trials. Results 16/23 trials (n = 2063) were selected. Corticosteroids did not change 28 day mortality (15 trials, n = 2022; relative risk 0.92, 95% confidence interval 0.75 to 1.14) or hospital mortality (13 trials, n = 1418; 0.89, 0.71 to 1.11). There was significant heterogeneity. Subgroup analysis on long courses (≥ 5 days) with low dose (≤ 300 mg hydrocortisone or equivalent) corticosteroids showed no more heterogeneity. The relative risk for mortality was 0.80 at 28 days (five trials, n = 465; 0.67 to 0.95) and 0.83 at hospital discharge (five trials, n = 465, 0.71 to 0.97). Use of corticosteroids reduced mortality in intensive care units (four trials, n = 425, 0.83, 0.70 to 0.97), increased shock reversal at 7 days (four trials, n = 425; 1.60, 1.27 to 2.03) and 28 days (four trials, n = 425, 1.26, 1.04 to 1.52) without inducing side effects. Conclusions For all trials, regardless of duration of treatment and dose, use of corticosteroids did not significantly affect mortality. With long courses of low doses of corticosteroids, however, mortality at 28 days and hospital morality was reduced.

[1]  Djillali Annane,et al.  Current epidemiology of septic shock: the CUB-Réa Network. , 2003, American journal of respiratory and critical care medicine.

[2]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[3]  G. S. Hughes,et al.  Naloxone and methylprednisolone sodium succinate enhance sympathomedullary discharge in patients with septic shock. , 1984, Life sciences.

[4]  W. Schumer Steroids in the Treatment of Clinical Septic Shock , 1976, Annals of surgery.

[5]  P. Bollaert,et al.  Reversal of late septic shock with supraphysiologic doses of hydrocortisone. , 1998, Critical care medicine.

[6]  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock , 2003, Current infectious disease reports.

[7]  B. Allolio,et al.  Cortisol response to corticotropin and survival in septic shock , 1991, The Lancet.

[8]  J. Klastersky,et al.  Effectiveness of betamethasone in management of severe infections. A double-blind study. , 1971, The New England journal of medicine.

[9]  M. Haller,et al.  Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. , 1999, Critical care medicine.

[10]  The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. , 1985, The New England journal of medicine.

[11]  C. Sprung,et al.  The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. , 1984, The New England journal of medicine.

[12]  R. Lefering,et al.  Steroid controversy in sepsis and septic shock: a meta-analysis. , 1995, Critical care medicine.

[13]  C. Howard,et al.  Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis. , 1996, The Pediatric infectious disease journal.

[14]  F. Keleştimur,et al.  Physiological-dose steroid therapy in sepsis [ISRCTN36253388] , 2002, Critical care.

[15]  Maximilians-Universitat Munchen Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study , 2005 .

[16]  L. Lasagna,et al.  The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. , 1956, Bulletin of the Johns Hopkins Hospital.

[17]  M. Cooper,et al.  Corticosteroid insufficiency in acutely ill patients. , 2003, The New England journal of medicine.

[18]  P. Rothwell,et al.  Cortisol response to corticotropin and survival in septic shock , 1991, The Lancet.

[19]  N. Tritos Corticosteroid insufficiency in acutely ill patients. , 2003, The New England journal of medicine.

[20]  G. Meduri,et al.  Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. , 1998, JAMA.

[21]  Douglas G Altman,et al.  Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.

[22]  Y. Kupfer,et al.  HYDROCORTISONE REVERSES REFRACTORY SEPTIC SHOCK , 1999 .

[23]  D. Annane,et al.  Corticosteroids for treating severe sepsis and septic shock. , 2004, The Cochrane database of systematic reviews.

[24]  The Cardiopulmonary Response to Massive Doses of Steroids in Patients with Septic Shock , 1984, Archives of surgery.

[25]  D. Annane,et al.  A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. , 2000, JAMA.

[26]  M. Doğanay,et al.  Physiological-dose steroid therapy in sepsis , 2002 .

[27]  J. Weigelt,et al.  Early steroid therapy for respiratory failure. , 1985, Archives of surgery.

[28]  J. Weigelt,et al.  Early steroid therapy for respiratory failure. , 1986, Archives of surgery.

[29]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[30]  J. Mckee,et al.  CORTISOL REPLACEMENT IN SEVERELY STRESSED PATIENTS , 1983, The Lancet.

[31]  The Veterans Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. , 1987, The New England journal of medicine.

[32]  T. Clemmer,et al.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. , 1987, The New England journal of medicine.

[33]  D. Cook,et al.  Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. , 1995, Critical care medicine.

[34]  F. W. Denny,et al.  Effect of cortisone on acute streptococcal infections and poststreptococcal complications. , 1951, The Journal of clinical investigation.

[35]  R F Woolson,et al.  The dynamics of disease progression in sepsis: Markov modeling describing the natural history and the likely impact of effective antisepsis agents. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  H. Volk,et al.  Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. , 2003, American journal of respiratory and critical care medicine.

[37]  D. Annane,et al.  Corticosteroids in Sepsis: From Bench to Bedside? , 2003, Shock.

[38]  J. Murray,et al.  Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. , 1988, The American review of respiratory disease.

[39]  G. Chrousos,et al.  Duration of glucocorticoid treatment and outcome in sepsis: is the right drug used the wrong way? , 1998, Chest.